Smith+Nephew announces Non-Executive Director Marc Owen as next Senior Independent Director

– UK, London –  Smith & Nephew plc (LON: SN | NYSE: SNN) today announced the appointment of current Non-Executive Director Marc Owen as Senior Independent Director effective from 30 September 2022, to succeed Robin Freestone who has decided to step down from the Board at the same date.

About Marc Owen

Mr. Owen was appointed as a Non-Executive Director in October 2017. In addition to his appointment as Senior Independent Director, Marc Owen will continue in his role as Chair of the Compliance & Culture Committee and as a member of the Audit Committee and Nomination & Governance Committee.

About Smith+Nephew

Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration, and replacement of soft and hard tissue. We exist to restore people’s bodies and their self-belief by using technology to take the limits off living. We call this purpose ‘Life Unlimited’. Our 18,000 employees deliver this mission every day, making a difference in patients’ lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global franchises of Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management.

Founded in Hull, UK, in 1856, we now operate in more than 100 countries and generated annual sales of $5.2 billion in 2021. Smith+Nephew is a constituent of the FTSE100 (LON: SN, NYSE: SNN). The terms ‘Group’ and ‘Smith+Nephew’ are used to refer to Smith & Nephew plc and its consolidated subsidiaries unless the context requires otherwise.

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.